CA-NETAPP
1.12.2021 14:02:14 CET | Business Wire | Press release
NetApp® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, today announced new innovations in its product portfolio as well as award recognition from Amazon Web Services (AWS) for its achievements as an AWS Partner. Together, these announcements demonstrate how NetApp's investments and vision are enabling any organization using AWS to access world-class cloud operations (CloudOps) and maximize the value of their investment.
At AWS re:Invent this week, NetApp was named the 2021 AWS Independent Software Vendor (ISV) Design Partner of the Year - US, for the jointly engineered and natively integrated Amazon FSx for NetApp ONTAP service. This fully-managed, multi-protocol storage service from AWS allows organizations to extend on-premises data onto AWS for enhanced data protection, migrate enterprise workloads without refactoring, and set the stage to run stateful Kubernetes applications. The award recognizes NetApp’s work in helping customers enable innovation and build solutions that drive digital and cloud transformation on the AWS Cloud.
“AWS Partners are critical to our customers’ success, and we are pleased to recognize NetApp as a 2021 AWS Partner of the Year US winner,” said Rachel Mushahwar, Head of Channel and Partner Sales - Americas, AWS. “I continue to be impressed by the commitment and innovation that NetApp offers our customers and how they are uniquely positioned to help accelerate our customers’ digital transformation journey. I look forward to working together and a great 2022.”
“We are proud to be named the AWS ISV Design Partner of the Year in the US," said Anthony Lye, Executive Vice President and General Manager of Public Cloud Services at NetApp. "For nearly a decade, NetApp and AWS engineers have worked together to create industry-leading cloud services, so it's incredibly exciting to see our joint innovation be recognized onstage at this year’s re:Invent. Together, NetApp and AWS are delivering the best of cloud to our customers and partners to deliver immediate business value, whether in the form of cost efficiency, compliance, data protection, or performance."
NetApp also announced important milestones in the growth of its Spot by NetApp product portfolio for CloudOps, including:
Spot Ocean for Apache Spark
Part of the Spot Ocean suite of products, Spot Ocean for Apache Spark combines the infrastructure automation and optimization of Spot Wave together with Data Mechanics, recently acquired by NetApp, to give data infrastructure teams the power and flexibility of Apache Spark on Kubernetes without the complexity of managing and tuning infrastructure and workloads. Ocean for Apache Spark
is now available in preview for AWS customers.
Spot Ocean Continuous Delivery (CD)
Also, part of the Spot Ocean suite, Spot Ocean CD extends Spot by NetApp’s core technologies with a solution for easy, reliable delivery of cloud-native applications on Kubernetes. Available for private preview with AWS customers in mid-December, Spot Ocean CD
makes it easy to quickly and reliably execute deployments with integrated and automated continuous verification to give developers full confidence in their deployments.
Together with Spot Ocean serverless infrastructure, these products make up the expanded Spot Ocean suite, bringing intelligent automation and optimization to cloud-native infrastructure and workloads on Kubernetes.
CloudCheckr Well-Architected Readiness Advisor
CloudCheckr, recently acquired by NetApp, complements the Spot product portfolio to expand Spot by NetApp’s financial operations (FinOps) capabilities. Spot by NetApp today announced the release of CloudCheckr Well-Architected Readiness Advisor, which helps managed service providers (MSPs) streamline the process of delivering AWS Well-Architected Reviews and helps to ensure that AWS customers are in compliance with the AWS Well-Architected Framework for optimization of cloud cost, security, operations, performance and reliability.
The Well-Architected Readiness Advisor is available on the CloudCheckr CMx platform.
Spot Security
Spot Security enables customers to quickly detect, prioritize and help mitigate the most serious security threats and risks within cloud infrastructure. Spot Security
is now available in private preview, starting with AWS customers.
“Getting applications to the cloud is only the first step in the cloud journey,” said Amiram Shachar, Vice President and General Manager of Spot by NetApp. “Realizing the promise of cloud requires a holistic approach to operating within the cloud, an approach that addresses cost, resource management, optimization and security. Our growing portfolio delivers a compelling suite of solutions for cloud operations that let organizations focus on their applications rather than on infrastructure.”
Additional Resources:
- Spot Ocean Suite Blog
- Spot Ocean for Apache Spark Blog
- CloudCheckr Well-Architected Readiness Advisor Blog
About NetApp
NetApp is a global, cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com
or follow us on Twitter
, LinkedIn
, Facebook
, and Instagram
.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005381/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
